What's in Matthew Neal MD's pipeline?

Matthew Neal MD has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Matthew Neal MD's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Beijing Anzhen Hospital, Beijing Chao Yang Hospital, Beijing Suncadia Pharmaceuticals Co., Ltd, Boston Scientific Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/matthew-neal-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Matthew Neal MD — Portfolio Competitive Intelligence Brief

Matthew Neal MD pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
P2Y12	P2Y12	marketed			Hematology
Metformin ER	Metformin ER	marketed
theraputic heparin	theraputic heparin	marketed
Crizanlizumab Injection	Crizanlizumab Injection	marketed	P-selectin inhibitor monoclonal antibody	P-selectin	Hematology/Oncology
prophylactic heparin	prophylactic heparin	marketed	Anticoagulant	Antithrombin III (indirect); Factors IIa and Xa	Cardiovascular

Therapeutic area mix

Cardiovascular · 1
Hematology · 1
Hematology/Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Beijing Anzhen Hospital · 1 shared drug class
Beijing Chao Yang Hospital · 1 shared drug class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 shared drug class
Boston Scientific Corporation · 1 shared drug class
CCRF Consulting Co., Ltd. · 1 shared drug class
Deutsches Herzzentrum Muenchen · 1 shared drug class
Anemia Working Group Romania · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Matthew Neal MD:

Cite this brief

Drug Landscape (2026). Matthew Neal MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/matthew-neal-md. Accessed 2026-05-16.